JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18+
SponsorJiangsu Alphamab Biopharmaceuticals Co., Ltd
About this trial
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.
Eligibility criteria
Qualifiers
Voluntary participation and written informed consent.
≥18 years;
Histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Confirmed platinum-resistant relapse.
Disqualifiers
Primary platinum-refractory disease.
Active central nervous system metastases.
Uncontrolled pleural effusion.
Previous treatment with topoisomerase I inhibitor ADCs.
Trial design
Treatments tested in this trial
- JSKN003
- Doxorubicin
- Paclitaxel
- Topotecan
Treatment groups
430 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov